ALNY — Alnylam Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $41.40bn
- $41.19bn
- $3.71bn
Annual cashflow statement for Alnylam Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -853 | -1,131 | -440 | -278 | 314 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 326 | 581 | 480 | 534 | 602 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -163 | -35.6 | 10.8 | -214 | -445 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -642 | -541 | 104 | -8.31 | 524 |
| Capital Expenditures | -76.4 | -72.1 | -62.2 | -34.3 | -58.7 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -197 | 241 | -274 | -82.6 | 495 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -273 | 169 | -336 | -117 | 436 |
| Financing Cash Flow Items | 501 | 31 | 24.7 | -8.79 | -2.41 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1,247 | 426 | 172 | 294 | -305 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 323 | 46.4 | -53.7 | 154 | 690 |